Memantine

An N-methyl-D-aspartate (NMDA) receptor antagonist.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

1
Supporting references
0
Contradictory references
8
AI-suggested references
0
Clinical trials

General information

Memantine is a drug approved for Alzheimer’s disease treatment. It acts as a N-methyl-D-aspartate (NMDA) receptor antagonist, by which it blocks the effects of glutamate (DrugBank).

Memantine on PubChem
Memantine on Wikipedia


Marketed as

MEMANTINE HYDROCHLORIDE; NAMENDA (MEMANTINE HYDROCHLORIDE)

 

Structure image - Memantine

CC12CC3CC(C1)(CC(C3)(C2)N)C


Supporting references

Link Tested on Impact factor Notes Publication date
SARS-CoV-2 E protein is a potential ion channel that can be inhibited by Gliclazide and Memantine
Envelope protein Small molecule In vitro
In vitro ion channel assay 2.99

Blocks the SARS-CoV-2 E protein ion channel in vitro.

Jun/20/2020

AI-suggested references